COMMUNIQUÉS West-GlobeNewswire

Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference
14/02/2025
-Interim clinical study updates for the first three Subjects treated with BB-301 in the Phase 1b/2a Clinical Treatment Study to be presented as a late-breaking oral presentation at the 2025 Muscular Dystrophy [...]
Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment
14/02/2025
Case Reports in the Journal of the American College of Cardiology Underscore the Critical Role of Blood Volume Analysis in Optimizing Heart Failure Treatment Oak Ridge, TN, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Daxor [...]
PetVivo Signs Exclusive Sales and Marketing Agreement with VetStem for PrecisePRP® Canine and Equine Products
14/02/2025
MINNEAPOLIS, MN, Feb. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leader in innovative veterinary medical solutions, has entered into an Exclusive License and Supply Agreement [...]
Enlitic, Inc. to Showcase AI Enabled Workflows at ViVE 2025
14/02/2025
Enlitic to be a first-time participant at this show Highlights Dates: February 16-19, 2025 Location: Nashville Music City Center, Nashville, TN Enlitic Booth: 2308 FORT COLLINS, Colo., Feb. 14, 2025 (GLOBE NEWSWIRE) -- [...]
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025
14/02/2025
Study mirrored 4 highest doses used in China dose escalation study presented at ASCO 2024 Safety, tolerability and PK comparable to China dataset with no DLTs observed in either study Low levels of peripheral neuropathy [...]
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
14/02/2025
MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative [...]
Theratechnologies annoncera ses résultats financiers du quatrième trimestre et de l’exercice 2024 et fera une mise à jour de ses activités
14/02/2025
MONTRÉAL, 14 févr. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique spécialisée axée sur la commercialisation de [...]
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
14/02/2025
The company is on track to complete the interim data analysis before the end of Q1 2025 and to submit the findings to the U.S. Food And Drug Administration (FDA) PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus [...]
Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™
14/02/2025
Study Demonstrates Robust Efficacy and Strong Safety Profile PHOENIX, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ) , a [...]
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
14/02/2025
WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2024 [...]
NeuroPace Announces Pricing of Public Offering of $65 Million of Common Stock
14/02/2025
MOUNTAIN VIEW, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a public offering price [...]
Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow
13/02/2025
TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]
Outset Medical Announces Resolution of Warning Letter
13/02/2025
SAN JOSE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, [...]
NeuroPace Announces Proposed Public Offering of $65 Million of Common Stock
13/02/2025
MOUNTAIN VIEW, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced that it intends to offer and sell, in an underwritten public offering, $65 million of shares of its common stock. [...]
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
13/02/2025
WARREN, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech company, [...]
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
13/02/2025
Efficacy Comparable to Approved Autologous CD19 CAR Ts: Achieved Overall Response (ORR) and Complete Response (CR) Rates of 58% and 42% Across the Study and 67% and 58% with Pivotal Study Regimen, Respectively [...]
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
13/02/2025
AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF [...]
Precision Optics Reports Second Quarter Fiscal Year 2025 Financial Results
13/02/2025
Conference Call Scheduled for today, February 13, 2025, at 5:00pm ET. GARDNER, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced [...]
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
13/02/2025
SAN DIEGO and TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based [...]

Pages